Stockscreener 앱 받기
74.89
3.43%
-2.66
시장 영업 전:
74.60
-0.29
-0.39%
Incyte Corp 주식(INCY)의 최신 뉴스
Barclays initiates coverage on Incyte stock with Overweight rating By Investing.com - Investing.com Canada
Incyte (INCY) Receives Overweight Rating and $90 Price Target fr - GuruFocus
Incyte's new CEO outlines growth plan as Jakafi patent cliff nears - MSN
Why is Incyte Corporation stock attracting strong analyst attentionBest Dividend Insights For Consistent Profits - jammulinksnews.com
Incyte’s Earnings Call: Strong Growth Amid Challenges - The Globe and Mail
Incyte stock price target raised to $72 from $68 at RBC Capital - Investing.com Canada
Incyte stock price target raised to $60 from $52 at BMO Capital - Investing.com Canada
Incyte Corporation (NASDAQ:INCY) Q2 2025 Earnings Call Transcript - Insider Monkey
Sun Pharma settles litigation with Incyte Corp over hair loss drug Leqselvi - MSN
Incyte Corp (INCY) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
Incyte: Q2 Earnings Snapshot - Norwalk Hour
Incyte Corp (INCY) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Incyte Raises Its Outlook After Beating Expectations On Jakafi Sales - Finimize
Incyte stock price target raised to $79 by Truist on strong Jakafi sales - Investing.com Canada
Incyte stock price target raised to $89 from $86 at TD Cowen on strong Q2 - Investing.com Canada
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Incyte earnings beat by $0.17, revenue fell short of estimates - Investing.com
Incyte’s Blood Cancer Drug Sales Forecast Gets A Lift - Finimize
Celestica, Corning, And Incyte Impress With Upbeat Quarterly Results - Finimize
Incyte lifts annual sales forecast for blood cancer drug after solid quarter - whbl.com
INCY's Q2 Earnings & Revenues Beat Estimates on Higher Product Sales - Yahoo Finance
Incyte Surges Past Expectations With Strong Q2, Boosts Guidance On Jakafi Demand - Benzinga
Earnings call transcript: Incyte Q2 2025 reveals revenue miss, stock gains - Investing.com
Incyte (INCY) Reports Q2 Earnings: What Key Metrics Have to Say - Nasdaq
Incyte Q2 Results Top Estimates - Nasdaq
Incyte Corp. Achieves Strong Financial Performance in Q2News and Statistics - IndexBox
Incyte Q2 2025 slides: revenue up 16%, raises guidance on strong product performance - Investing.com
Incyte (INCY) Surpasses Q2 Earnings and Revenue Estimates - Nasdaq
Incyte Corp reports results for the quarter ended June 30Earnings Summary - TradingView
Incyte misses Q2 earnings estimates, raises Jakafi guidance By Investing.com - Investing.com Canada
Incyte misses Q2 earnings estimates, raises Jakafi guidance - Investing.com
Incyte Corp Q2 2025 Earnings: EPS of $2.04 and Revenue of $1.216 Billion Surpass Estimates - GuruFocus
Incyte Reports 2025 Second Quarter Financial Results - TradingView
Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs - Business Wire
How Is Incyte’s Stock Performance Compared to Other Biotech Stocks? - MSN
Incyte (INCY) Anticipates Q2 Earnings with Positive Expectations - GuruFocus
How volatile is Incyte Corporation stock compared to the marketRealize exceptional returns through smart trading - jammulinksnews.com
Does Incyte Corporation stock perform well during market downturnsNavigate market shifts with confidence - jammulinksnews.com
What makes Incyte Corporation stock attractive to long term investors5x Profit Potential - metal.it
Why Incyte Corporation stock attracts strong analyst attentionQuick Profit Idea Stream - beatles.ru
Earnings Preview: Incyte to Report Financial Results Pre-market on July 29 - 富途牛牛
Incyte Corp (INCY) Price Target Hiked at UBS on Sales and Earnings Growth Prospects - MSN
Incyte Gears Up to Report Q2 Earnings: Is a Beat in the Cards? - MSN
Incyte to present initial data on cancer therapies at ESMO Congress - Investing.com
Incyte To Present Initial Data for its TGFβR2×PD-1-directed Bispecific Antibody (INCA33890) and its Selective Inhibitor of G12D-mutated KRAS (INCB161734) at the European Society of Medical Oncology (ESMO) Congress 2025 - Business Wire
What analysts say about Incyte Corporation stockFree Buy/Sell Signal Notifications - Autocar Professional
What drives Incyte Corporation stock priceHigh-impact stock picks - jammulinksnews.com
Incyte (INCY) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
0.86%
2.00%
자본화:
|
볼륨(24시간):